NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway

Background: Gemcitabine is widely used in the treatment of breast cancer (BC). However, the resistance to drugs remains a tough concern. The study explored the potential mechanism concerning gemcitabine resistance in triple-negative BC (TNBC) in vitro. Methods: TNBC cells (TNBCC) and gemcitabine-res...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Qiao, Yao, Dejiao, Cai, Yi, Zhou, Tiecheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2020
Materias:
Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335831/
https://www.ncbi.nlm.nih.gov/pubmed/32578856
http://dx.doi.org/10.1042/BSR20200730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335831/
https://www.ncbi.nlm.nih.gov/pubmed/32578856
http://dx.doi.org/10.1042/BSR20200730

Ejemplares similares